Expanded Access Study Assessing Efficacy and Safety of Nivolumab in Italian Patients with Stage IIIB/Stage IV Non-Small-Cell-Lung-Cancer: A Real World Experience

Trial Profile

Expanded Access Study Assessing Efficacy and Safety of Nivolumab in Italian Patients with Stage IIIB/Stage IV Non-Small-Cell-Lung-Cancer: A Real World Experience

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 18 Oct 2017 Results reporting analysis of patients treated beyond progressive disease, presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results (As of March 2017) assessing efficacy and safety of Nivolumab monotherapy in patients with non-squamous non-small cell lung cancer, presented at the 18th World Conference on Lung Cancer
    • 18 Oct 2017 Results of Italian Nivolumab expanded access programme presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top